Watch FULC. Know when insiders buy.
One email the day a filing lands. Free.
FULC
Fulcrum Therapeutics, Inc.
3.78
−0.01 −0.26%
USD · close Sep 15
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
37
FLAG · shorts 37
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $288.4MP/E —DIV YIELD —FCF YIELD -22.93%REV TTM —NET INCOME −$85MNET CASH —52W 3.14 – 14.60SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$29.3M | −$26.2M | — | -0.34 | −$16M | $108K | −$16.1M | Jul 30 |
| Q1 2026 · Mar 31 | — | — | — | −$22.2M | −$18.9M | — | -0.25 | −$18.8M | $8K | −$18.8M | Jul 30 |
| Q4 2025 · Dec 31derived | — | — | — | −$22.7M | −$20.3M | — | -0.31 | −$16.8M | $159K | −$17M | Feb 24 |
| Q3 2025 · Sep 30 | — | — | — | −$21.9M | −$19.6M | — | -0.31 | −$14.2M | $90K | −$14.3M | Oct 29 |
| Q2 2025 · Jun 30 | — | — | — | −$19.8M | −$17.3M | −131.2% | -0.28 | −$13.8M | $65K | −$13.9M | Jul 30 |
| Q1 2025 · Mar 31 | — | — | — | −$20.4M | −$17.7M | — | -0.28 | −$15.3M | $0 | −$15.3M | Jul 30 |
| Q4 2024 · Dec 31derived | — | — | — | −$19.4M | −$16.6M | — | -0.27 | −$16.8M | $231K | −$17M | Feb 24 |
| Q3 2024 · Sep 30 | — | — | — | −$25.1M | −$21.7M | — | -0.35 | −$19.1M | $19K | −$19.1M | Oct 29 |
| Q2 2024 · Jun 30 | — | — | — | $52.5M | $55.4M | — | 0.87 | $58.9M | $0 | $58.9M | Oct 29 |
| Q1 2024 · Mar 31 | — | — | — | −$29.8M | −$26.9M | — | -0.43 | −$25.3M | $28K | −$25.3M | Oct 29 |
| Q4 2023 · Dec 31derived | — | — | — | −$28M | −$24.8M | — | -0.40 | −$23.2M | $77K | −$23.2M | Feb 25 |
| Q3 2023 · Sep 30 | — | — | — | −$27.4M | −$24M | — | -0.39 | −$22.9M | $65K | −$23M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$84.8M | −$74.9M | — | -1.18 | −$60.1M | $314K | −$60.4M | — | — |
| FY2024 · to Dec 31 | — | — | −$21.9M | −$9.7M | — | -0.16 | −$2.2M | $278K | −$2.5M | — | — |
| FY2023 · to Dec 31 | — | — | −$110.7M | −$97.3M | — | -1.59 | −$91M | $508K | −$91.5M | — | — |
| FY2022 · to Dec 31 | — | — | −$112.6M | −$109.9M | — | -2.44 | −$97M | $2M | −$99M | — | — |
| FY2021 · to Dec 31 | — | — | −$81.1M | −$80.8M | — | -2.29 | −$78.5M | $1.7M | −$80.2M | — | — |
| FY2020 · to Dec 31 | — | — | −$71.6M | −$70.8M | — | -2.79 | −$53.7M | $1.3M | −$55M | — | — |
Every number comes from Fulcrum Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.